Evidence map›Paper›PMID 33349975›Full record

ArticleAdvanced materials (Deerfield Beach, Fla.)2021

Sensing of COVID-19 Antibodies in Seconds via Aerosol Jet Nanoprinted Reduced-Graphene-Oxide-Coated 3D Electrodes.

Md Azahar Ali, Chunshan Hu, Sanjida Jahan, Bin Yuan, Mohammad Sadeq Saleh, Enguo Ju, Shou-Jiang Gao, Rahul Panat

Abstract read
In one paragraph

Article in Advanced materials (Deerfield Beach, Fla.), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 115 papers.

0numbers the graph read from it
0cells of the map it votes in
115citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

115 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. 2D Materials in Advanced Electronic Biosensors for Point-of-Care Devices.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024
    Review
  17. Article
  18. Review
  19. Review
  20. Article

55 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Md Azahar AliDepartment of Mechanical Engineering, Carnegie Mellon University, Pittsburgh, PA, 15213, USA.
Chunshan HuDepartment of Mechanical Engineering, Carnegie Mellon University, Pittsburgh, PA, 15213, USA.
Sanjida JahanDepartment of Mechanical Engineering, Carnegie Mellon University, Pittsburgh, PA, 15213, USA.
Bin YuanDepartment of Mechanical Engineering, Carnegie Mellon University, Pittsburgh, PA, 15213, USA.
Mohammad Sadeq SalehDepartment of Mechanical Engineering, Carnegie Mellon University, Pittsburgh, PA, 15213, USA.
Enguo JuCancer Virology Program, UPMC Hillman Cancer Center and Department of Microbiology and Molecular Genetics, University of Pittsburgh School of Medicine, Pittsburgh, PA, 15213, USA.
Shou-Jiang GaoCancer Virology Program, UPMC Hillman Cancer Center and Department of Microbiology and Molecular Genetics, University of Pittsburgh School of Medicine, Pittsburgh, PA, 15213, USA.
Rahul PanatDepartment of Mechanical Engineering, Carnegie Mellon University, Pittsburgh, PA, 15213, USA.ORCID https://orcid.org/0000-0002-4824-2936

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Rapid diagnosis is critical for the treatment and prevention of diseases. An advanced nanomaterial-based biosensing platform that detects COVID-19 antibodies within seconds is reported. The biosensing platform is created by 3D nanoprinting of three-dimensional electrodes, coating the electrodes by nanoflakes of reduced-graphene-oxide (rGO), and immobilizing specific viral antigens on the rGO nanoflakes. The electrode is then integrated with a microfluidic device and used in a standard electrochemical cell. When antibodies are introduced on the electrode surface, they selectively bind with the antigens, changing the impedance of the electrical circuit which is detected via impedance spectroscopy. Antibodies to SARS-CoV-2 spike S1 protein and its receptor-binding-domain (RBD) are detected at a limit-of-detection of 2.8 × 10

Indexed as

ElectrodesAerosolsAntibodies, ViralAntigens, ViralBiosensing TechniquesCOVID-19Dielectric SpectroscopyElectrochemical TechniquesGraphiteHumansHydrogen-Ion ConcentrationNanostructuresNanotechnologyPrinting, Three-DimensionalProtein DomainsSpike Glycoprotein, CoronavirusAerosolsAntibodies, ViralAntigens, Viralgraphene oxideGraphiteSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-23D printing3D sensorsantibody testsCOVID-19gold nanoparticlesmicropillarspandemicsreduced graphene oxide

Identifiers

PMID33349975
PMCPMC7883076

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.